Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results01/04/2026
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes01/04/2026
Clare Stones joins Rollits as trust administratorBy News Team09/05/2024 Rollits, an esteemed Yorkshire legal firm, has appointed Clare Stones as a trust administrator in its private capital team.Clare Stones brings a wealth of experience from…
Soligenix (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results01/04/2026
